Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Found vs HealthRX

Two GLP-1 desks, one scoreboard. We put Found and HealthRX head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

Higher Brief ScoreNo. 5 · Grade B+

Found

Visit Found Full brief →
vs
No. 17 · Grade B

HealthRX

Visit HealthRX Full brief →

The verdict

Found takes this head-to-head.

Found scores 88 to 86 on our six-factor Brief Score — A coaching-first program with the lowest identical price on both molecules — if you want the coaching lock-in that comes with it.

That doesn't make HealthRX a bad call — it's best for readers who want an accredited, physician-supervised program with a needle-free oral tablet option on either molecule — and value a legitscript trust signal, while accepting that some tiers are company-stated. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
88
85
Supply Reliability
88
85
Transparency
88
83
Access Breadth
88
91
Clinical Oversight
90
89
Track Record
86
81
FoundBrief Score 88 · 86HealthRX

Price, coverage & the tracker

FoundHealthRX
Brief Score88/100 (B+)86/100 (B)
Semaglutide$129/mo$189/mo
Tirzepatide$129/mo$349/mo
CoverageAll 50 statesNot publicly listed
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

Found: Lowest identical-price line on the board — but bundled into a coaching subscription.

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.